| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
126,570,000 |
| Market
Cap: |
621.46(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.81 - $12.27 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with unmet medical need. Co. has commercially launched LUPKYNIS in the U.S. for the treatment of adult patients with active LN, and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
65,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$404,759 |
| Total People Bought |
0 |
0 |
0 |
4 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
323,922 |
323,922 |
347,210 |
474,747 |
| Total Sell Value |
$1,807,847 |
$1,807,847 |
$2,069,886 |
$3,199,812 |
| Total People Sold |
6 |
6 |
11 |
11 |
| Total Sell Transactions |
8 |
8 |
13 |
19 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Martin Michael Robert |
Chief Business Officer |
• – – |
2021-09-07 |
4 |
AS |
$18.10 |
$135,750 |
D/D |
(7,500) |
176,861 |
|
2% |
|
| Huizinga Robert Bindert |
EVP of Research |
• – – |
2021-09-07 |
4 |
AS |
$18.30 |
$91,500 |
D/D |
(5,000) |
138,592 |
|
2% |
|
| Martin Michael Robert |
Chief Business Officer |
• – – |
2021-08-26 |
4 |
AS |
$17.81 |
$400,725 |
D/D |
(22,500) |
184,361 |
|
5% |
|
| Solomons Neil |
Chief Medical Officer |
• – – |
2021-08-25 |
4 |
AS |
$15.85 |
$79,250 |
D/D |
(5,000) |
137,299 |
|
19% |
|
| Solomons Neil |
Chief Medical Officer |
• – – |
2021-08-09 |
4 |
AS |
$16.03 |
$721,350 |
D/D |
(45,000) |
142,299 |
|
25% |
|
| Martin Michael Robert |
Chief Business Officer |
• – – |
2021-08-09 |
4 |
AS |
$16.01 |
$80,050 |
D/D |
(5,000) |
206,861 |
|
25% |
|
| Martin Michael Robert |
Chief Business Officer |
• – – |
2021-07-28 |
4 |
AS |
$13.86 |
$69,300 |
D/D |
(5,000) |
211,861 |
|
34% |
|
| Martin Michael Robert |
Chief Business Officer |
• – – |
2021-06-22 |
4 |
AS |
$13.76 |
$68,800 |
D/D |
(5,000) |
216,861 |
|
114% |
|
| Mackay-Dunn R. Hector |
Director |
– • – |
2021-05-12 |
4 |
B |
$11.26 |
$33,804 |
D/D |
3,000 |
6,000 |
2.39 |
101% |
|
| Mackay-Dunn R. Hector |
Director |
– • – |
2021-05-11 |
4 |
B |
$11.14 |
$16,725 |
D/D |
1,500 |
3,000 |
2.39 |
86% |
|
| Martin Michael Robert |
Chief Business Officer |
• – – |
2021-05-11 |
4 |
OE |
$3.02 |
$60,400 |
D/D |
20,000 |
221,861 |
|
- |
|
| Donley Matthew Maxwell |
Ex VP, Internl Operations |
• – – |
2021-05-11 |
4 |
B |
$10.07 |
$99,739 |
D/D |
9,900 |
9,900 |
2.74 |
86% |
|
| Greenleaf Peter |
Chief Executive Officer |
• • – |
2021-05-11 |
4 |
B |
$10.15 |
$54,891 |
D/D |
5,125 |
13,453 |
2.81 |
86% |
|
| Leversage Jill |
Director |
– • – |
2021-05-11 |
4 |
B |
$10.96 |
$27,389 |
D/D |
2,500 |
3,700 |
2.39 |
86% |
|
| Huizinga Robert Bindert |
Ex Vice President of Research |
• – – |
2021-05-11 |
4 |
OE |
$3.02 |
$120,800 |
D/D |
40,000 |
143,592 |
|
- |
|
| Miller Joseph M |
Chief Financial Officer |
• – – |
2021-05-11 |
4 |
B |
$9.74 |
$9,740 |
D/D |
1,000 |
1,000 |
2.74 |
86% |
|
| Solomons Neil |
Chief Medical Officer |
• – – |
2021-03-12 |
4 |
S |
$13.49 |
$539,600 |
D/D |
(40,000) |
187,299 |
|
16% |
|
| Solomons Neil |
Chief Medical Officer |
• – – |
2021-03-12 |
4 |
OE |
$3.02 |
$120,800 |
D/D |
40,000 |
227,299 |
|
- |
|
| Milne George M Jr |
Director |
– • – |
2021-03-05 |
4 |
B |
$13.00 |
$65,000 |
D/D |
5,000 |
45,000 |
2.39 |
-13% |
|
| Hayden Michael R |
Director |
– • – |
2021-01-29 |
4 |
OE |
$5.44 |
$550,100 |
D/D |
95,000 |
95,000 |
|
- |
|
| Leversage Jill |
Director |
– • – |
2021-01-29 |
4 |
B |
$16.03 |
$19,236 |
D/D |
1,200 |
1,200 |
2.39 |
-24% |
|
| Leversage Jill |
Director |
– • – |
2021-01-29 |
4 |
B |
$16.03 |
$6,412 |
I/I |
400 |
400 |
2.1 |
-24% |
|
| Robertson Stephen P. |
EVP, General Counsel |
• – – |
2021-01-28 |
4 |
B |
$16.14 |
$14,526 |
D/D |
900 |
2,720 |
2.74 |
-26% |
|
123 Records found
|
|
Page 5 of 5 |
|
|
0.04 (0.82%) 
